Previous article Next article

See translation in english Spain: The Spanish Competition Authority (CNMC) fines the two main suppliers of PET radiopharmaceuticals (in particular, 18F-FDG, a drug used in radiodiagnosis by positron emission tomography), as well as two of their managers, for sharing the market for supply contracts for this drug for at least four years (Radiofármacos)

CHRONIQUES : DROITS EUROPÉENS ET ÉTRANGERS - ESPAGNE - CARTEL - RÉPARTITION DE MARCHÉS - AMENDES

Spain : The Spanish Competition Authority (CNMC) fines the two main suppliers of PET radiopharmaceuticals (in particular, 18F-FDG, a drug used in radiodiagnosis by positron emission tomography), as well as two of their managers, for sharing the market for supply contracts for this drug for at least four years (Radiofármacos)

Radiopharmaceuticals are commonly used in nuclear medicine for detecting and monitoring diseases such as cancer. Currently, Advanced Accelerator Applications Ibérica (AAA) and Curium Pharma Spain, are the sole companies with sufficient capacity and means to provide hospitals throughout Spain with this drug, a circumstance that eased the collusion and had an impact on the determination of the conditions of contracts the CNMC’s decision states. The CNMC found that the sanctioned conduct affected both public and private hospitals located in various regions of Spain, by increasing the price of the service provided to patients in need of this drug. This conduct would have been implemented at least from June 2014 to November 2018, when the CNMC carried out inspections at the headquarters of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Rafael Allendesalazar, Spain: The Spanish Competition Authority (CNMC) fines the two main suppliers of PET radiopharmaceuticals (in particular, 18F-FDG, a drug used in radiodiagnosis by positron emission tomography), as well as two of their managers, for sharing the market for supply contracts for this drug for at least four years (Radiofármacos), 9 February 2021, Concurrences N° 2-2021, Art. N° 100466, pp. 225-226

Visites 23

All reviews